Strut Health Safety, Regulation & Compliance Posture: An Independent Review

What Strut Health Actually Sells

Strut Health positions itself as a direct-to-consumer telehealth brand focused on compounded medications. Its product catalog spans oral finasteride, topical finasteride-minoxidil combinations, sildenafil and tadalafil compounds, tretinoin blends, and select peptide formulations. The business model skips insurance entirely, charging flat monthly fees for consultations and medications bundled together.

Compounded vs. FDA-Approved Products

A key distinction matters here. Some Strut Health products contain FDA-approved active ingredients (finasteride, minoxidil, sildenafil) but are dispensed as compounded formulations. The FDA defines compounded drugs as medications created to meet individual patient needs that differ from commercially available versions. These products do not undergo the same premarket approval process as manufactured drugs. The FDA has stated that compounded drugs "are not FDA-approved" and that patients "may be exposed to additional risks" including inconsistent potency and contamination [1].

Multi-Active Formulations

Strut Health's topical hair loss products often combine finasteride with minoxidil and sometimes dutasteride or biotin in a single application. While each active ingredient has individual evidence supporting its use for androgenetic alopecia, the specific combinations and concentrations in Strut Health's proprietary blends have not been evaluated in published randomized controlled trials. A 2022 systematic review in the Journal of the American Academy of Dermatology found that topical finasteride at concentrations of 0.1% to 0.25% reduced scalp DHT levels by 30% to 40% with lower systemic absorption than oral finasteride [2]. That supports the general concept, but not the specific multi-ingredient blend.

Regulatory Framework for Telehealth Prescribing

Telehealth prescribing in the United States operates under a patchwork of state medical board regulations. Every state requires that a valid prescriber-patient relationship exist before a prescription can be written. The Federation of State Medical Boards (FSMB) sets model policy, but enforcement falls to individual state boards.

Asynchronous Consultation Risks

Strut Health uses asynchronous consultations for most products, meaning a patient fills out a questionnaire and uploads photos, then a prescriber reviews the submission without a live interaction. The American Medical Association has noted that asynchronous care can be appropriate for low-acuity conditions but carries higher diagnostic error rates compared to synchronous (video or in-person) visits for conditions requiring nuanced clinical assessment [3]. For straightforward pattern hair loss in a 28-year-old male, that risk is modest. For ED in a 55-year-old with undiagnosed cardiovascular disease, the gap between a questionnaire and a proper workup could be clinically meaningful.

State Licensure Verification

Strut Health states that all prescribers are licensed in the patient's state. Patients can verify this claim through their state medical board's license lookup tool. This is a standard practice across legitimate telehealth platforms including Hims, Ro, and Lemonaid Health. The DEA's Ryan Haight Act requires at least one in-person evaluation before prescribing controlled substances online, which is why Strut Health does not prescribe Schedule II drugs like Adderall. Its ED medications (sildenafil, tadalafil) are not scheduled substances and can legally be prescribed via telehealth in all 50 states.

Compounding Pharmacy Oversight

Strut Health partners with a 503A compounding pharmacy. Understanding the difference between 503A and 503B facilities matters for safety assessment.

503A vs. 503B Pharmacies

Under the Drug Quality and Security Act of 2013, 503A pharmacies compound drugs based on individual prescriptions, are regulated primarily by state boards of pharmacy, and receive less direct FDA oversight. 503B outsourcing facilities register with the FDA, must comply with current Good Manufacturing Practice (cGMP) requirements, and undergo FDA inspections [4]. Strut Health's partner pharmacy operates under Section 503A, which means its products are not subject to FDA cGMP requirements and are not routinely inspected by the FDA unless a safety signal triggers an investigation.

Historical Compounding Safety Events

The compounding industry has a documented history of safety events. The 2012 New England Compounding Center (NECC) meningitis outbreak killed 76 people and sickened 753, leading directly to the passage of the DQSA [5]. More recently, in 2023, the FDA issued warning letters to multiple compounding pharmacies for sterility failures and potency inaccuracies. While these events do not implicate Strut Health's specific pharmacy partner, they illustrate the structural risks inherent in the 503A model.

Patients cannot independently verify batch testing results for Strut Health's compounded products. The platform does not publish certificates of analysis (COAs), third-party testing data, or beyond-use dating studies on its website.

Safety Assessment: Product by Product

Hair Loss Products

Strut Health's hair loss line centers on finasteride and minoxidil. Oral finasteride 1 mg daily is FDA-approved for male androgenetic alopecia, with a well-characterized safety profile from the original Phase III trials showing sexual side effects (decreased libido, erectile dysfunction, decreased ejaculate volume) in 3.8% of men vs. 2.1% on placebo [6]. The 20-year follow-up from Rossi et al. (2011) demonstrated sustained efficacy with a side effect incidence below 5% across long-term use [7].

Strut Health's topical formulations aim to reduce systemic exposure. A 2023 meta-analysis in Dermatologic Therapy covering 6 studies and 561 patients found topical finasteride produced comparable hair count improvements to oral finasteride with lower rates of sexual adverse events (1.1% vs. 3.6%) [8]. The specific carrier vehicles and concentrations used by Strut Health, however, may not match those studied.

Erectile Dysfunction Products

Sildenafil and tadalafil are PDE5 inhibitors with decades of post-marketing surveillance data. The FDA label for sildenafil lists contraindications including concurrent nitrate use, which can cause fatal hypotension [9]. Strut Health's intake questionnaire asks about nitrate use, but an asynchronous format depends entirely on patient self-reporting for this screening. A prospective cohort study of 1,473 men using telehealth for ED found that 4.2% had at least one unidentified contraindication on initial screening, with nitrate co-prescription being the most common [10].

HealthRX Telehealth Safety Scoring Framework

To give consumers a structured way to evaluate telehealth platforms, HealthRX developed a 5-domain scoring framework based on regulatory standards, clinical guideline adherence, and transparency metrics. Each domain scores 1 (poor) to 5 (excellent).

| Domain | What It Measures | Strut Health Score | |---|---|---| | Prescriber Transparency | License verification, credentials listed, supervising physician named | 3/5 | | Clinical Screening Depth | Contraindication capture, lab requirements, follow-up protocols | 2/5 | | Pharmacy Oversight Level | 503A vs. 503B, cGMP compliance, COA availability | 2/5 | | Adverse Event Reporting | Published AE data, clear reporting pathways, MedWatch integration | 2/5 | | Regulatory Compliance Record | State board actions, FDA warning letters, BBB complaints | 3/5 |

Composite score: 12/25. This places Strut Health in the "adequate with gaps" tier. Platforms scoring 18+ in this framework (typically those using 503B pharmacies, requiring labs for certain prescriptions, and publishing clinical outcome data) earn a "strong compliance posture" designation.

How Strut Health Compares to Alternatives

The direct-to-consumer telehealth space for men's health has become crowded. Comparing compliance posture across major players reveals meaningful differences.

Hims & Hers

Hims (now Hims & Hers Health, NYSE: HIMS) went public in 2021 and files quarterly earnings with the SEC, providing financial transparency that privately held companies like Strut Health cannot match. Hims uses both manufactured FDA-approved products and compounded formulations. Its platform offers synchronous video consultations for certain conditions and has published patient outcome data in peer-reviewed journals [11]. Hims also established an internal clinical advisory board with named physicians.

Ro (Roman)

Ro requires a synchronous consultation for ED prescriptions and mandates blood pressure documentation in certain cases. Ro partnered with a 503B outsourcing facility for some compounded products, providing a higher manufacturing oversight tier than Strut Health's 503A model. Ro has also published real-world evidence studies in peer-reviewed dermatology journals.

Lemonaid Health (now Amazon Clinic)

Acquired by Amazon in 2022, Lemonaid Health / Amazon Clinic operates under Amazon's corporate compliance infrastructure. It primarily prescribes FDA-approved manufactured medications rather than compounded alternatives, reducing the pharmacy-level safety risk variable entirely.

Key Differences

Strut Health differentiates on price and on offering multi-ingredient compounded formulations that competitors may not carry. This differentiation comes with a tradeoff: less regulatory oversight of the pharmacy, less published clinical data, and fewer layers of clinical screening.

Patient Review Analysis

Online reviews of Strut Health across Trustpilot, Reddit, and the BBB paint a mixed picture. Common positive themes include affordable pricing, ease of the ordering process, and satisfaction with hair loss products specifically. Common negative themes include slow customer service response times, difficulty obtaining refunds, and limited follow-up after prescribing.

Red Flags to Watch For

The FTC's Health Products Compliance Guidance identifies several warning signs in telehealth platforms: auto-enrollment in subscription billing without clear consent, difficulty canceling, claims of "FDA-approved" for compounded products (which are never FDA-approved as formulated), and prescribing without adequate medical history [12]. Patients should verify that any telehealth provider clearly distinguishes between FDA-approved drugs and compounded formulations in its marketing.

A 2024 cross-sectional study in JAMA Network Open analyzing 128 direct-to-consumer telehealth platforms found that 41% made at least one misleading claim about regulatory status on their websites, and only 23% provided prescriber credentials in a verifiable format [13].

What the Evidence Supports

The active ingredients Strut Health prescribes (finasteride, minoxidil, sildenafil, tadalafil, tretinoin) all have strong evidence bases as individual compounds. Finasteride reduces hair loss progression in approximately 83% of men over 2 years based on the Kaufman et al. (1998) Phase III data [6]. Sildenafil produces erections sufficient for intercourse in 69% to 84% of men across doses, per the Goldstein et al. (1998) key trial (N=532) [14].

The gap is not in the drugs themselves. The safety question centers on three factors: whether the compounding process maintains drug quality, whether the asynchronous screening catches contraindications, and whether follow-up monitoring is adequate. On all three, Strut Health provides less transparency than its larger competitors.

Who Should Consider Strut Health

Strut Health may be reasonable for otherwise healthy young men seeking straightforward hair loss treatment who have been previously evaluated by a physician and want a lower-cost maintenance option. The American Academy of Dermatology guidelines on androgenetic alopecia recommend that patients have at least one in-person dermatological evaluation to confirm the diagnosis before starting treatment [15].

Patients with cardiovascular disease, those taking multiple medications, anyone over 50 seeking ED treatment for the first time, and anyone considering peptide products should pursue a more comprehensive clinical evaluation, either through a telehealth platform offering synchronous consultations with lab requirements, or through an in-person provider.

Men currently taking alpha-blockers, nitrates, or CYP3A4 inhibitors should not rely on a questionnaire-based screen for PDE5 inhibitor prescriptions. The ACC/AHA guidelines on stable ischemic heart disease specifically flag PDE5 inhibitor-nitrate interactions as a contraindication requiring active clinical assessment [16].